Non-GAAP EPS was updated to account for the financing of the recent acquisitions and non-GAAP tax rate was updated to approximately 69% to reflect the impact of a $12.1B one-time, non-tax-deductible IPRD charge from the Karuna Therapeutics acquisition, which is expected to contribute 51% to the full-year tax rate, the company stated. As previously communicated, Bristol Myers Squibb is updating portions of its 2024 line-item guidance, including non-GAAP EPS, to reflect the impact of recent transactions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- BMY Earnings this Week: How Will it Perform?
- Bristol Myers price target lowered to $52 from $55 at Cantor Fitzgerald
- Bristol Myers and Cellares sign $380M agreement for CAR T cell therapies
- Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
- Bristol Myers price target raised to $52 from $51 at Wells Fargo
